Low-Dose Methylprednisolone

Phase 3Small molecule

QQingyuan Zhan

Low-Dose Methylprednisolone is one of 55 small molecule programs targeting Pneumonia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoniaActive, not recruiting

InfluenzaActive, not recruiting

PneumoniaPhase 3

Active, not recruiting

InfluenzaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Fluzone

Sanofi

Preclinical

16 2

Low-Dose Methylprednisolone

QQingyuan Zhan

Phase 3

1 3

Fluzone

GSK

Preclinical

37 4

Trexall

Alnylam Pharmaceuticals

Preclinical

1 5

Avigan

AAppili Therapeutics Inc.

Preclinical

6 6

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 7

COMIRNATY

Pfizer

Preclinical

1 8

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

1 9

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 10

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Not yet recruiting

Pneumonia

NCT07152600

Q4 2028

Phase 3Not yet recruiting

Influenza

NCT07351500

Phase 3Not yet recruiting

Pneumonia

NCT07352865

Clinical

Trials by Indication[1]

Pneumonia2 trials

Adaptive RCT of Corticosteroids for Severe Adenovirus Pneumonia in Adults

Not yet recruiting·QQingyuan Zhan·Phase 3·NCT07152600·262 enrolled

Adaptive RCT of Corticosteroids for Severe Chlamydia Psittaci Pneumonia in Adults

Not yet recruiting·QQingyuan Zhan·Phase 3·NCT07352865·100 enrolled

Glucocorticoid1 trial

Multi-center Prospective Clinical Study on Glucocorticoid Pulse Therapy for Graves' Ophthalmopathy (GO)

Enrolling by invitation·ZZou Junjie·N/A·NCT06693856·120 enrolled

Influenza1 trial

Adaptive RCT of Corticosteroids for Severe Influenza Pneumonia in Adults

Not yet recruiting·QQingyuan Zhan·Phase 3·NCT07351500·496 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Low-Dose Methylprednisolone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Low-Dose Methylprednisolone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Low-Dose Methylprednisolone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Qingyuan Zhan company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: QQingyuan Zhan

Low-Dose Methylprednisolone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2028

Trials by Indication[1]

Pneumonia2 trials

Glucocorticoid1 trial

Influenza1 trial

References

Drug Info

Quick Facts

Related News